Meropenem Wh (Meropenem Anhydrous)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the final step of peptidoglycan cross‑linking. This inhibition weakens the cell wall, causing osmotic rupture and bacterial cell death, and it remains active against many β‑lactamase‑producing organisms.

The dose of Meropenem Wh is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. Healthcare professionals calculate the appropriate infusion rate and duration for each individual case.

Safety data for meropenem during pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Meropenem Wh, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Meropenem shares the broad‑spectrum activity of the carbapenem class but offers a slightly wider gram‑negative coverage and greater stability against many β‑lactamases compared with imipenem. Compared with non‑carbapenem agents, it provides more reliable efficacy against multidrug‑resistant organisms, though choice of therapy should follow local susceptibility patterns and stewardship principles.

Meropenem Wh should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The powder should be reconstituted with the appropriate diluent immediately before intravenous administration, and any unused solution should be discarded according to local regulations.

Meropenem Wh is supplied as a sterile powder that is reconstituted with a compatible diluent and administered by intravenous infusion. The infusion rate and duration are set by the prescribing clinician, typically over 15‑30 minutes, and the medication may be given once or multiple times daily depending on the infection and patient factors.

Serious risks include anaphylactic reactions, seizures (especially in patients with renal impairment or pre‑existing CNS disorders), and Clostridioides difficile‑associated colitis, which can be life‑threatening. Prompt recognition and medical intervention are essential if any of these events occur.

Meropenem Wh should be avoided in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or a history of severe C. difficile infection, as the drug may exacerbate these conditions.